Retatrutide versus semaglutide: different stages of evidence

Compare evidence stages, not Instagram winners

Semaglutide is a GLP-1 receptor agonist with completed Phase 3 obesity trials, FDA-approved branded products for diabetes and chronic weight management, and a cardiovascular-outcomes trial in people with overweight or obesity and established heart disease. Retatrutide is a GIP, GLP-1, and glucagon triple agonist that remains investigational in the United States as of August 2026. Lilly has reported Phase 3 TRIUMPH toplines and plans a Q1 2027 application. Those are not the same regulatory category.

This article is educational, not medical advice. It does not name a best drug for you. It does not claim Beema's compounded semaglutide is better than retatrutide or better than Wegovy. Beema does not currently offer retatrutide.

One receptor versus three

Semaglutide occupies the GLP-1 receptor. That is enough to reduce energy intake substantially in STEP trials. Retatrutide adds GIP and glucagon receptor activity. Researchers hope the extra glucagon signaling increases energy expenditure. Extra receptors also mean extra things to monitor, including pulse rate in Phase 2.

Mechanism diagrams are not dosing instructions. Nobody should stack unregulated glucagon agonists onto semaglutide to 'simulate retatrutide.'

Numbers you can cite without pretending they are head-to-head

STEP 1 (Wilding et al., 2021): adults with overweight or obesity without diabetes, semaglutide 2.4 mg versus placebo for 68 weeks, mean body-weight change about 14.9% versus 2.4%. Gastrointestinal events were common. SELECT later showed fewer major cardiovascular events with semaglutide 2.4 mg in a high-risk obesity population without diabetes.

Retatrutide Phase 2 (Jastreboff et al., 2023): 48 weeks, 12 mg dose mean change about 24.2% versus 2.1% placebo. TRIUMPH-3 company release (July 2026): 12 mg mean 22.6% at 80 weeks versus 3.2% placebo in severe obesity with cardiovascular disease. Those TRIUMPH figures were topline at announcement; peer-reviewed full papers were still pending.

You cannot subtract 14.9 from 24.2 and call the difference 'how much better retatrutide is for me.' Duration, diet run-in, diabetes status, and dropout handling all differ.

Safety files are not the same length

Semaglutide's labeled risks - gastrointestinal effects, gallbladder disease, pancreatitis warnings, pregnancy avoidance, and the rodent thyroid C-cell boxed warning on obesity products - are documented in FDA prescribing information. Retatrutide will need its own label if approved. Phase 2 already described dose-related GI effects and heart-rate increases. Unknowns remain around long-term cardiovascular outcomes for the triple agonist.

Unregulated 'retatrutide' vials have no label at all. That is the worst of both worlds.

What you can be prescribed today

A U.S. clinician can prescribe FDA-approved semaglutide products when indicated, or other approved obesity medicines. Beema Health's cash-pay telehealth program may offer compounded semaglutide or compounded tirzepatide after independent review. Compounded semaglutide is not FDA-approved and is considered only when legally available and clinically appropriate. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate. Retatrutide is none of those channels except a sponsored trial.

If your question is 'which molecule has more Phase 3 obesity plus CV data today,' the answer is semaglutide. If your question is 'which investigational mean looks larger,' retatrutide's early figures are larger and unfinished. Neither sentence tells Beema to call compounded semaglutide the winner.

A decision framework that stays honest

Write down your constraints: diabetes or not, heart disease or not, injection willingness, pregnancy plans, cost, and how long you can wait. Bring that list to a licensed provider. If you use Beema, complete intake accurately. A prescription is never guaranteed.

For more on the investigational drug itself, read the retatrutide explainer. For branded diabetes-dose semaglutide, read the Ozempic education page. For how clinicians compare several GLP-1-class options, read 'best GLP-1 for weight loss' as a process article, not a trophy.

Frequently asked questions

Sources

1. [1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023.
2. [2] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
3. [3] Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023.
4. [4] Eli Lilly. TRIUMPH-2 and TRIUMPH-3 topline results and planned Q1 2027 BLA. July 23, 2026.